Update on the use of memantine in Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 237-247

  Van Marum, Robert J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alzheimer's disease; Dementia; Drug therapy; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIVASTIGMINE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BINDING AFFINITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DELUSION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; FATIGUE; FOOD; FOOD DRUG INTERACTION; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERTENSION; INFECTION; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MYCOSIS; NEUROTOXICITY; NOTE; PANCREATITIS; PSYCHOPATHY; PSYCHOSIS; RECOMMENDED DRUG DOSE; SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 70449732262     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Note

References (61)

1. Gerzon K, et al. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N′-adamantylureas. J Med Chem. 1963;6:760-763.
2. Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(1):87-93. (Pubitemid 16132817)
3. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135-146. (Pubitemid 29110331)
4. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-1341.
5. NICE technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). National Institute for Health and Clinical Excellence. London; Sept 2007.
6. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7(1):39-47. (Pubitemid 46238036)
7. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699-723. (Pubitemid 47532143)
8. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7(8):742-755.
9. Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis. 2006;10(1):81-87. (Pubitemid 44401369)
10. Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(4):247-252 (Pubitemid 47482070)
11. European Medicines Agency: European Public Assessment Report (EPAR) http://www.emea.europa.eu/humandocs/PDFs/EPAR/ebixa/160402en6.pdf
12. Shua-Haim J, Smith J, Picard F, et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig. 2008;28(6):361-374. (Pubitemid 351685393)
13. Yao C, Raoufinia A, Gold M, et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol. 2005;45(5):519-528. (Pubitemid 40562942)
14. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother. 2004;38(9):1389-1394 (Pubitemid 39100189)
15. Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134-143. (Pubitemid 43069584)
16. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Remy UG, Gleiter CH. Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol. 1998;46:541-546. (Pubitemid 28522117)
17. Winblad B, Wimo A, Almkvist O. Outcome measures in Alzheimer's disease: do they go far enough? Dement Geriatr Cogn Disord. 2000;11 suppl 1:3-10. (Pubitemid 30687515)
18. Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr. 2007;19(3):421-456. (Pubitemid 46707434)
19. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11 suppl 2:S51-S56. (Pubitemid 27303110)
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
21. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11 suppl 2:S33-S39. (Pubitemid 27303108)
22. van der Kam P, Mol F, Wimmers MFHC. Beoordelingsschaal voor oudere patienten (BOP). Deventer, The Netherlands: Van Loghum Slaterus; 1971.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314. (Pubitemid 24382728)
24. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; the Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-143.
25. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324. (Pubitemid 38101604)
26. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21(5):327-340. (Pubitemid 36403437)
27. Rive B, Vercelletto M, Damier FD, Cochran J, François C. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19(5):458-464. (Pubitemid 38697039)
28. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63(1):49-54. (Pubitemid 43063861)
29. van Dyck CH, Schmitt FA, Olin JT. Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006;14(5):428-437.
30. Cummings JL, Schneider E, Tariot PN, Graham SM; Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67(1):57-63.
31. Schmitt FA, van Dyck CH, Wichems CH, Olin JT; the Memantine MEM-MD-02 Study Group. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006;20(4):255-262.
32. Feldman HH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006;20(4):263-268.
33. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704-715. (Pubitemid 44196270)
34. Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord. 2007;21(1):60-64. (Pubitemid 46398957)
35. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97-107.
36. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.
37. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
38. Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis. 2008;14(2):193-199. (Pubitemid 352040033)
39. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20-27. (Pubitemid 46985287)
40. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-145. (Pubitemid 47094073)
41. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007;3(1):7-17. (Pubitemid 46076022)
42. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397. (Pubitemid 351665469)
43. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother. 2008;42(1):32-38
44. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341-438 (Pubitemid 351549385)
45. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31(3):193-200.
46. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187-1197. (Pubitemid 46799603)
47. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-526. (Pubitemid 47403186)
48. François C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a markov model in Finland. Clin Drug Investig. 2004;24(7):373-384. (Pubitemid 38951789)
49. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain. Eur J Health Econ. 2006;7(2):137-144. (Pubitemid 44562258)
50. Kirby J, Green C, Loveman E, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease. Drugs Aging. 2006;23(3):227-240.
51. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess. 2006;10(1):iii-iv, ix-xi, 1-160. (Pubitemid 43322990)
52. Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother. 2005; 3(2):77-86. (Pubitemid 41200509)
53. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging. 2004;21(9):607-620. (Pubitemid 39070995)
54. Geldmacher DS Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review. Neuropsychiatr Dis Treat. 2008;4(3):549-555.
55. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004;63:644-650. (Pubitemid 39100819)
56. Neumann, PJ. Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Pharmacoeconomics. 2005;23:437-541.
57. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31(7):577-585 (Pubitemid 351861950)
58. European Medicines Agency: Summary of Product Characteristics http://www.emea.europa.eu/humandocs/PDFs/EPAR/ebixa/H-463-PI-en.pdf
59. Ott BR, Blake LM, Kagan E, Resnick M; the Memantine MEMMD-11AB Study Group. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol. 2007;254(3):351-358. (Pubitemid 46399200)
60. Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(3):258-262. (Pubitemid 46431716)
61. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-221.